POC(Point-of-Care) 분자진단 시장 : 제품 및 서비스별, 기술별, 샘플 유형별, 용도별, 최종 사용자별 세계 예측(-2030년)

The global point-of-care molecular diagnostics market is projected to reach USD 7.09 billion by 2030, from USD 4.30 billion in 2025, with a CAGR of 10.5%. The market is primarily driven by the increasing focus on decentralized testing, which facilitates faster clinical decisions across various care settings. This is especially crucial in resource-limited or remote areas where timely decision-making is vital.

Rising R&D investments are further supporting the development of advanced, portable technologies that make molecular testing easier while maintaining reliability. These innovations are helping healthcare providers adopt point-of-care solutions outside traditional laboratory settings.

Assays & kits accounted for the highest growth rate in the point-of-care molecular diagnostics market by product & service.

The point-of-care molecular diagnostics market is classified into assays & kits, instruments & analyzers, and software & services. Assays & kits are expected to be the fastest-growing segment during the forecast period. This growth is fueled by the rising need for quick and precise testing solutions that can be used directly at the point of care. The frequent use and ongoing demand for assay kits across various clinical settings, as well as their growing role in diagnosing diverse conditions, are key factors supporting this trend. As healthcare systems continue to prioritize early detection and decentralized testing, the demand for reliable and easy-to-use molecular assay kits is likely to increase steadily.

Blood is the fastest-growing segment in the point-of-care molecular diagnostics market by sample type.

The point-of-care molecular diagnostics market includes various sample types, such as blood, urine, and others. The blood sample is expected to experience the highest CAGR during the forecast period, driven by its broad use across different diseases and the availability of minimally invasive collection methods. Blood-based molecular tests provide high sensitivity and specificity, making them suitable for detecting a wide range of infectious diseases, including HIV, hepatitis, and sepsis. The increasing demand for rapid diagnostics in critical care settings, where blood is often the preferred sample, further supports this growth. Additionally, technological advancements have improved the efficiency and reliability of blood-based point-of-care testing, promoting its wider adoption.

Asia Pacific exhibits the fastest growth in the point-of-care molecular diagnostics market.

The global market for point-of-care molecular diagnostics is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is expected to experience the fastest growth in this market. This expansion is fueled by increasing healthcare spending, broader access to diagnostic services, and more government efforts to improve early disease detection. Additionally, ongoing investments in healthcare infrastructure and rising awareness of the benefits of point-of-care testing create positive conditions for market growth. The presence of emerging economies like China and India further boosts growth prospects due to their growing focus on enhancing diagnostic capabilities.

The break-up of the profile of primary participants in the point-of-care molecular diagnostics market:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa - 4%

The key players in this market are Danaher Corporation (US), bioMerieux (France), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), QIAGEN N.V. (Netherlands), QuidelOrtho Corporation (US), Co-Diagnostics, Inc. (US), Biocartis Group NV (Belgium), SD Biosensor, INC. (South Korea), genedrive plc (UK), Binx Health, Inc. (US), Molbio Diagnostics Pvt. Ltd. (India), Genomadix (Canada), Visby Medical, Inc. (US), QuantuMDx Group Ltd. (UK), DetectaChem (US), Labsystems Diagnostics Oy (Finland), Akonni Biosystems, Inc. (US), Ubiquitome Limited (New Zealand), Credo Diagnostics Biomedical Pte. Ltd. (Singapore), OpGen, Inc. (US), Nuclein, LLC (US), Genes2Me (India), Axxin (Australia), and Huwel Lifesciences (India).

Research Coverage:

This report categorizes the point-of-care molecular diagnostics market by product & service (assay & kits, instruments & analyzers, and software & services), technology (RT-PCR, INAAT, other technologies), sample type (blood samples, urine, and other sample types), application (respiratory diseases, sexually transmitted diseases, hospital-acquired infections, cancer, hepatitis, gastrointestinal disorders, and other applications), end user (physicians' offices/clinics, hospitals, research institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report includes detailed information about the major factors affecting the growth of the point-of-care molecular diagnostics market, such as drivers, restraints, opportunities, and challenges. A thorough analysis of key industry players has been conducted to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. The report also covers new product launches and recent developments related to the point-of-care molecular diagnostics market. Additionally, it includes a competitive analysis of upcoming startups within the point-of-care molecular diagnostics market ecosystem.

Reasons to buy this report:

The report will assist market leaders and new entrants by providing near-accurate estimates of the revenue for the overall point-of-care molecular diagnostics market and its subsegments. It will help stakeholders understand the competitive landscape and gain insights to better position their businesses and develop effective go-to-market strategies. Additionally, the report offers stakeholders an understanding of market dynamics, including key drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (rising incidence of infectious diseases and cancer, increasing focus on decentralized diagnostics, improved awareness of early detection of infectious diseases), opportunities (untapped growth potential across emerging economies), restraints (unfavorable reimbursement scenario, substantial initial investment and low cost-benefit ratio), and challenges (stringent and time-consuming regulatory policies, emergence of alternative technologies) influencing the growth of the point-of-care molecular diagnostics market
• Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and new product launches in the point-of-care molecular diagnostics market
• Market Development: Comprehensive information about lucrative markets - the report analyses the point-of-care molecular diagnostics market across varied regions
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the point-of-care molecular diagnostics market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Danaher Corporation (US), bioMerieux (France), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), and QIAGEN N.V. (Netherlands)

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 KEY STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH APPROACH
  • 2.2.1 SECONDARY DATA
    • 2.2.1.1 Key secondary sources
    • 2.2.1.2 Key data from secondary sources
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Primary sources
    • 2.2.2.2 Key data from primary sources
    • 2.2.2.3 Key industry insights
    • 2.2.2.4 Breakdown of primary interviews
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Approach 1: Company revenue estimation approach
    • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
    • 2.3.1.3 Growth forecast
    • 2.3.1.4 CAGR projections
  • 2.3.2 TOP-DOWN APPROACH
• 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.5 MARKET SHARE ASSESSMENT
• 2.6 RESEARCH ASSUMPTIONS
  • 2.6.1 PARAMETRIC ASSUMPTIONS
• 2.7 RESEARCH LIMITATIONS
• 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET OVERVIEW
• 4.2 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
• 4.3 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
• 4.4 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION)
• 4.5 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
• 4.6 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
• 4.7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing prevalence of infectious diseases and cancer
    • 5.2.1.2 Increasing focus on decentralized diagnostics and subsequent rise in R&D funding
    • 5.2.1.3 Growing awareness associated with early disease diagnosis
    • 5.2.1.4 Increasing use of POC diagnostic tests
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Unfavorable reimbursements
    • 5.2.2.2 High capital investments and low cost-benefit ratio
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growth opportunities in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Stringent regulatory guidelines that impact product commercialization
    • 5.2.4.2 Introduction of alternative technologies
• 5.3 PRICING ANALYSIS
  • 5.3.1 AVERAGE PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS, 2023-2025
  • 5.3.2 AVERAGE PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC ASSAYS & KITS, BY KEY PLAYER, 2023-2025
  • 5.3.3 AVERAGE SELLING PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS, BY REGION, 2023-2025
• 5.4 PATENT ANALYSIS
  • 5.4.1 LIST OF KEY PATENTS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 TRADE ANALYSIS
  • 5.7.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS
  • 5.7.2 IMPORT DATA (HS CODE 3822)
  • 5.7.3 EXPORT DATA (HS CODE 3822)
• 5.8 ECOSYSTEM ANALYSIS
  • 5.8.1 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 THREAT OF NEW ENTRANTS
  • 5.9.2 BARGAINING POWER OF SUPPLIERS
  • 5.9.3 THREAT OF SUBSTITUTES
  • 5.9.4 BARGAINING POWER OF BUYERS
  • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY FRAMEWORK
    • 5.10.1.1 North America
      • 5.10.1.1.1 US
      • 5.10.1.1.2 Canada
    • 5.10.1.2 EUROPE
      • 5.10.1.2.1 Germany
      • 5.10.1.2.2 UK
      • 5.10.1.2.3 France
      • 5.10.1.2.4 Italy
    • 5.10.1.3 Asia Pacific
      • 5.10.1.3.1 China
      • 5.10.1.3.2 Japan
      • 5.10.1.3.3 India
    • 5.10.1.4 Latin America
      • 5.10.1.4.1 Brazil
      • 5.10.1.4.2 Mexico
    • 5.10.1.5 Middle East
      • 5.10.1.5.1 Africa
  • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.11 TECHNOLOGY ANALYSIS
  • 5.11.1 KEY TECHNOLOGIES
    • 5.11.1.1 RT-PCR
  • 5.11.2 COMPLEMENTARY TECHNOLOGIES
    • 5.11.2.1 INAAT (Isolated Nucleic Acid Amplification Technology)
  • 5.11.3 ADJACENT TECHNOLOGIES
    • 5.11.3.1 CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 BUYING CRITERIA
• 5.15 INVESTMENT & FUNDING SCENARIO
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 CASE STUDY 1: RAPID POINT OF CARE PCR TESTING STREAMLINES EMERGENCY CARE FOR HOSPITAL IN GERMANY
  • 5.16.2 CASE STUDY 2: IMPLEMENTATION OF RAPID PCR TESTING TO IMPROVE NOROVIRUS DIAGNOSIS & BED MANAGEMENT
  • 5.16.3 CASE STUDY 3: USING MOLECULAR DIAGNOSTICS TO IDENTIFY ATYPICAL RESPIRATORY INFECTION
• 5.17 IMPACT OF AI/GENERATIVE AI IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
  • 5.17.1 INTRODUCTION
  • 5.17.2 MARKET POTENTIAL OF AI
  • 5.17.3 AI-USE CASES
  • 5.17.4 IMPLEMENTATION OF AI, BY KEY COMPANY & USE CASE
  • 5.17.5 FUTURE OF AI IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
• 5.18 TRUMP TARIFF IMPACT ON POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
  • 5.18.1 INTRODUCTION
  • 5.18.2 KEY TARIFF RATES
  • 5.18.3 PRICE IMPACT ANALYSIS
  • 5.18.4 IMPACT ON COUNTRY/REGION
    • 5.18.4.1 North America
    • 5.18.4.2 Europe
    • 5.18.4.3 Asia Pacific
  • 5.18.5 IMPACT ON END-USE INDUSTRIES
    • 5.18.5.1 Physicians' Offices/Clinics
    • 5.18.5.2 Hospitals
    • 5.18.5.3 Research Institutes

6 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
• 6.2 ASSAYS & KITS
  • 6.2.1 RECURRENT PURCHASE TO PROPEL MARKET
• 6.3 INSTRUMENTS & ANALYZERS
  • 6.3.1 INCREASING ADOPTION OF ADVANCED POC TECHNOLOGIES TO DRIVE MARKET
• 6.4 SOFTWARE & SERVICES
  • 6.4.1 UTILIZATION OF SOLUTIONS FOR ENHANCED USER EXPERIENCE TO SUPPORT MARKET GROWTH

7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 RT-PCR
  • 7.2.1 HIGH SENSITIVITY AND SPECIFICITY TO BOOST DEMAND
• 7.3 INAAT
  • 7.3.1 COST-BENEFITS AND RAPID AMPLIFICATION ABILITIES TO PROPEL MARKET
• 7.4 OTHER TECHNOLOGIES

8 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE

• 8.1 INTRODUCTION
• 8.2 BLOOD SAMPLES
  • 8.2.1 ABILITY TO SUPPORT RAPID DETECTION FOR SEVERAL DISEASES TO PROPEL MARKET
• 8.3 URINE SAMPLES
  • 8.3.1 NON-INVASIVE NATURE AND DETECTION OF LOW BIOMARKER CONCENTRATION TO BOOST DEMAND
• 8.4 OTHER SAMPLE TYPES

9 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 RESPIRATORY DISEASES
  • 9.2.1 RISING INCIDENCE OF INFLUENZA AND RSV TO DRIVE MARKET
• 9.3 SEXUALLY TRANSMITTED DISEASES
  • 9.3.1 RISING PREVALENCE OF HPV AND HIV TO DRIVE MARKET
• 9.4 HOSPITAL-ACQUIRED INFECTIONS
  • 9.4.1 GROWING FOCUS ON TARGETED CLINICAL THERAPY FOR REDUCTION IN HAIS TO FUEL MARKET
• 9.5 CANCER
  • 9.5.1 INCREASING PREFERENCE FOR ONCOLOGY THERAPEUTICS TO DRIVE MARKET
• 9.6 HEPATITIS
  • 9.6.1 INCREASING PREVALENCE AMONG HIGH-RISK SUBGROUP POPULATIONS TO PROPEL MARKET
• 9.7 GASTROINTESTINAL DISORDERS
  • 9.7.1 RISING INCIDENCE OF IBS TO SUPPORT MARKET GROWTH
• 9.8 OTHER APPLICATIONS

10 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS
  • 10.2.1 CAPABILITY TO PURCHASE ADVANCED DIAGNOSTIC EQUIPMENT AND ABILITY TO SUPPORT HIGH PATIENT FOOTFALL TO PROPEL MARKET
    • 10.2.1.1 Sepsis
      • 10.2.1.1.1 Rising requirement for rapid diagnosis & treatment to fuel uptake
    • 10.2.1.2 Gastroenteritis
      • 10.2.1.2.1 Increasing admissions to critical care units and rising focus on molecular tools for diagnosis to fuel uptake
    • 10.2.1.3 Meningoencephalitis
      • 10.2.1.3.1 Initialization of targeted treatment due to high mortality risk to fuel market
    • 10.2.1.4 Other diseases
• 10.3 PHYSICIANS' OFFICES/CLINICS
  • 10.3.1 RAPID RESULTS AND INDIVIDUALIZED CARE TO FUEL MARKET
• 10.4 RESEARCH INSTITUTES
  • 10.4.1 INCREASING FOCUS ON GENOMICS & PROTEOMICS RESEARCH TO BOOST DEMAND
• 10.5 OTHER END USERS

11 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 11.2.2 US
    • 11.2.2.1 High healthcare expenditure for advanced molecular diagnostic technologies to drive market
  • 11.2.3 CANADA
    • 11.2.3.1 Favorable government initiatives for early disease diagnosis awareness to fuel market
• 11.3 EUROPE
  • 11.3.1 EUROPE: MACROECONOMIC OUTLOOK
  • 11.3.2 GERMANY
    • 11.3.2.1 Universal healthcare coverage and favorable growth for decentralized care settings to fuel market
  • 11.3.3 UK
    • 11.3.3.1 Rising prevalence of STIs to boost demand
  • 11.3.4 FRANCE
    • 11.3.4.1 High disease burden of infectious diseases and cancer to drive market
  • 11.3.5 ITALY
    • 11.3.5.1 Rising demand for high-precision diagnostic tools to support market growth
  • 11.3.6 SPAIN
    • 11.3.6.1 Rising incidence of respiratory illnesses and HIV to boost demand
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 11.4.2 CHINA
    • 11.4.2.1 Increasing incidence of influenza and epidemics to propel market
  • 11.4.3 JAPAN
    • 11.4.3.1 Growing access to advanced & affordable healthcare services to fuel market
  • 11.4.4 INDIA
    • 11.4.4.1 Expanding healthcare access and increasing prevalence of HIV to propel market
  • 11.4.5 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 11.5.2 BRAZIL
    • 11.5.2.1 High incidence of hepatitis to support market uptake
  • 11.5.3 MEXICO
    • 11.5.3.1 Rising cases of TB and HAIs to fuel market
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
  • 11.6.2 KINGDOM OF SAUDI ARABIA (KSA)
    • 11.6.2.1 Improvements in healthcare infrastructure to drive market
  • 11.6.3 UNITED ARAB EMIRATES (UAE)
    • 11.6.3.1 Rising technological advancements in molecular diagnostics to fuel market
  • 11.6.4 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
• 12.3 REVENUE SHARE ANALYSIS, 2022-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Product & service footprint
    • 12.5.5.4 Technology footprint
    • 12.5.5.5 Application footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 12.6.5.1 Detailed list of key startups/SMEs
    • 12.6.5.2 Competitive benchmarking of key emerging players/startups (1/2)
    • 12.6.5.3 Competitive benchmarking of key startups/SMEs (2/2)
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/PRODUCT COMPARISON
  • 12.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 DANAHER CORPORATION
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products/Services offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product/Service launches & approvals
      • 13.1.1.3.2 Deals
      • 13.1.1.3.3 Expansions
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 BIOMERIEUX
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products/Services offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product/Service launches & approvals
      • 13.1.2.3.2 Deals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 F. HOFFMANN-LA ROCHE LTD.
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products/Services offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Products/Services launches & approvals
      • 13.1.3.3.2 Deals
      • 13.1.3.3.3 Expansions
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 ABBOTT
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products/Services offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Key strengths
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 QIAGEN N.V.
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products/Services offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Product launches & approvals
      • 13.1.5.3.2 Deals
      • 13.1.5.3.3 Expansions
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key strengths
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses & competitive threats
  • 13.1.6 QUIDELORTHO CORPORATION
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products/Services offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product/Service launches & approvals
      • 13.1.6.3.2 Deals
      • 13.1.6.3.3 Expansions
  • 13.1.7 CO-DIAGNOSTICS, INC.
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products/Services offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Deals
      • 13.1.7.3.2 Expansions
  • 13.1.8 BIOCARTIS
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products/Services offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product/Service launches & approvals
      • 13.1.8.3.2 Deals
  • 13.1.9 SD BIOSENSOR, INC.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products/Services offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product/Service launches
      • 13.1.9.3.2 Deals
      • 13.1.9.3.3 Other developments
  • 13.1.10 GENEDRIVE PLC
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products/Services offered
• 13.2 OTHER PLAYERS
  • 13.2.1 BINX HEALTH, INC.
  • 13.2.2 MOLBIO DIAGNOSTICS LIMITED
  • 13.2.3 OPGEN, INC.
  • 13.2.4 GENOMADIX
  • 13.2.5 VISBY MEDICAL, INC.
  • 13.2.6 QUANTUMDX GROUP LTD.
  • 13.2.7 DETECTACHEM
  • 13.2.8 LABSYSTEMS DIAGNOSTICS OY
  • 13.2.9 AKONNI BIOSYSTEMS, INC.
  • 13.2.10 UBIQUITOME LIMITED
  • 13.2.11 CREDO DIAGNOSTICS BIOMEDICAL PTE. LTD.
  • 13.2.12 NUCLEIN, LLC
  • 13.2.13 GENES2ME
  • 13.2.14 AXXIN
  • 13.2.15 HUWEL LIFESCIENCES

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS